SHANGHAI, May 21, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE : WX ), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced the launch of LabNetwork (www.labnetwork.com). LabNetwork is a global e-Commerce platform for connecting buyers and sellers of research chemicals and reagents. Backed by WuXi's world-class expertise in chemistry R&D, sourcing, and quality control, LabNetwork will bring trusted, novel, and high-quality compounds from WuXi's global network of qualified providers to the chemistry and research communities worldwide.
For researchers and chemists, LabNetwork provides sophisticated web and mobile tools that allow customers to search for compounds by either keyword or chemical structure, with intelligent ranking of results. With a platform built for speed and ease of use, buyers can make informed decisions based upon cost, speed of delivery, and product quality. LabNetwork features multi-language and multi-currency shopping capabilities, including quotation, ordering, and tracking.
Suppliers will be able to leverage LabNetwork's customizable platform, global warehousing, logistics, and compliance solutions to reach new customers and markets. LabNetwork provides capabilities to increase distribution channels, author Safety Data Sheets in over 45 languages, and develop Global Harmonized System compliant labels.
LabNetwork currently offers nearly 300,000 research chemicals from a dozen quality suppliers, including the WuXi catalog of over 112,000 screening compounds, building blocks, and other off-the-shelf compounds. Many more supplier catalogs will be added in the coming weeks and months.
"LabNetwork will be a catalyst to enable more efficient and cost-effective research," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "This initiative is an important step in advancing WuXi's mission to broaden our service offerings and enable scientists anywhere in the world to leverage the LabNetwork platform to conduct their research more efficiently and cost effectively."
For more information, please contact:
Ronald Aldridge (for investors)
Director, Investor Relations
Aaron Shi (for the media)
Director, Corporate Communications
SOURCE WuXi PharmaTech